Black Friday Tomorrow: buy 2, get a 3rd free on every product Buy 2 = get a 3rd free, on every product Tomorrow: 3rd one free Buy 2 = 3rd one free Starts inEnds in Shop now
Free shipping on orders from 160 €from 160 € · 3-vial Retatrutide 30 mg pack at 150 € See the packs
MyPeptide Blog
Shop Quality Certificates Blog Contact About
Order
MyPeptide
Shop Quality Certificates Blog Contact About
ORDER
MyPeptide Blog
Home Shop Quality Blog Contact My account
Order
Skip to content
MyPeptide Logo - European Research Peptide Shop
  • Home
  • Shop
  • Quality
  • Blog
  • Contact
  • About
  • My account
MyPeptide Logo - European Research Peptide Shop
  • About — MyPeptide Research Team
  • Buy KPV in Luxembourg: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy KPV in Belgium: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy KPV in France: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy retatrutide in Belgium: R3 Reta 10 mg at €59.90 | MyPeptide.eu
  • Buy GHK-Cu in Luxembourg: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy GHK-Cu in Belgium: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy GHK-Cu in France: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy Research Peptides in Europe | MyPeptide.eu
  • Acquistare GHK-Cu in Italia: prezzo, COA Janoshik e consegna | MyPeptide.eu
  • Acquistare KPV in Italia: price, COA Janoshik and instructions | MyPeptide.eu
  • AHK-Cu hair: what studies say, AHK-Cu or GHK-Cu, price | MyPeptide.eu
  • Anti-Aging Peptides Europe — GHK-Cu, BPC-157 & More
  • Blog
  • Buy GHK-Cu in Ireland: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy GHK-Cu in Malta: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy KPV in Ireland: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy KPV in Malta: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy Peptides in Ireland: Supplier Guide, COA and Delivery | MyPeptide.eu
  • Buy Research Peptides in Europe
  • Buy Retatrutide in Ireland: Price, COA and Supplier | MyPeptide.eu
  • Buy Retatrutide in Malta: Price, COA and Supplier | MyPeptide.eu
  • Cagrilintide: what is it, mechanism, tests and status
  • Cagrilintide: side effects and safety
  • CagriSema: Trial results, tirzepatide and the FDA
  • Peptide calculator: reconstitution (mg/ml) and half-life | MyPeptide.eu
  • Certificates of analysis
  • COA of tesamorelin: Janoshik 98.2% analysis and verification | MyPeptide.eu
  • Cagrilintide COA: Janoshik report 99.836%
  • GHK-Cu COA: 3 Janoshik analyses, recognizing genuine GHK-Cu | MyPeptide.eu
  • KLOW COA: 4 peptides measured by Janoshik
  • KPV COA: Janoshik report 98.8%
  • MOTS-c COA: Janoshik 99.553% analysis and verification | MyPeptide.eu
  • COA retatrutide: 7 verifiable Janoshik certificates of analysis | MyPeptide.eu
  • How to verify a Janoshik Certificate of Analysis (COA) in 5 steps
  • Comprar Cagrilintide em Portugal
  • Comprar GHK-Cu en España: precio, COA Janoshik y envío | MyPeptide.eu
  • Buy KPV in Portugal: preço, COA Janoshik and purchase | MyPeptide.eu
  • Buy KPV in Spain: price, COA of Janoshik and envío | MyPeptide.eu
  • Buy Retatrutide in Portugal: preço desde 5 €/mg, COA Janoshik | MyPeptide.eu
  • Comprar Retatrutide en España: precio desde 5 €/mg, COA Janoshik | MyPeptide.eu
  • Comprar Tirzepatide em Portugal
  • Terms of Use
  • General Terms and Conditions of Sale – MyPeptide
  • Contact details – Legal notice
  • Cumpără GHK-Cu în România: preț, COA Janoshik și livrare | MyPeptide.eu
  • Cumpără KPV în România: preț, COA Janoshik și livrare | MyPeptide.eu
  • Cumpără Retatrutide în România: preț, COA și furnizor | MyPeptide.eu
  • Bacteriostatic water: uses, pharmacy, price and storage | MyPeptide.eu
  • FAQ – Frequently Asked Questions about Research Peptides
  • GHK-Cu: A Complete Guide to Copper Peptide (Research, Forms, Prices) | MyPeptide.eu
  • GHK-Cu hair: what studies say, GHK-Cu or AHK-Cu | MyPeptide.eu
  • Injectable or cream-based GHK-Cu: What forms, what are the differences? | MyPeptide.eu
  • GHK-Cu kaufen in Deutschland: Preis, Janoshik-COA & Versand | MyPeptide.eu
  • GHK-Cu kaufen in Österreich: Preis, Janoshik-COA und Zustellung | MyPeptide.eu
  • GHK-Cu kopen in Nederland: prijs, Janoshik-COA en levering | MyPeptide.eu
  • GHK-Cu kupić w Polsce: cena, certyfikat Janoshik i dostawa | MyPeptide.eu
  • GHK-Cu vásárlás Magyarországon: ár, Janoshik COA és szállítás | MyPeptide.eu
  • GLP-3: What is it? Retatrutide, a triple agonist (price, COA) | MyPeptide.eu
  • Complete Guide to NAD+: Longevity, Sirtuins, and DNA Repair
  • Complete Guide to Retatrutide: Mechanisms, Research and Clinical Results
  • Home
  • Kjøp GHK-Cu i Norge: pris, Janoshik-COA og levering | MyPeptide.eu
  • Kjøp retatrutide i Norge: pris, COA og leverandør | MyPeptide.eu
  • Kjøpe KPV i Norge: taken, Janoshik-COA and levering | MyPeptide.eu
  • KLOW: Side effects, risks and reviews
  • KLOW benefits: what studies really say
  • KLOW peptide: what is it, composition, studies and price
  • KLOW vs GLOW vs Wolverine: what are the differences?
  • Køb GHK-Cu i Danmark: pris, Janoshik-COA og levering | MyPeptide.eu
  • Køb retatrutide i Danmark: pris, COA og leverandør | MyPeptide.eu
  • Købe KPV i Danmark: taken, Janoshik-COA and levering | MyPeptide.eu
  • Köp GHK-Cu i Sverige: pris, Janoshik-COA och leverans | MyPeptide.eu
  • Köp retatrutide i Sverige: pris, COA och leverantör | MyPeptide.eu
  • Köpa KPV i Sverige: taken, Janoshik-COA och leverans | MyPeptide.eu
  • Koupit GHK-Cu v Česku: cena, COA Janoshik a doručení | MyPeptide.eu
  • Koupit KPV v Česku: cena, COA Janoshik a doručení | MyPeptide.eu
  • Koupit retatrutide v Česku: cena, COA a dodavatel | MyPeptide.eu
  • KPV: studied benefits for the gut and skin
  • KPV: What is it, how does it work, research, and its status?
  • KPV: Side effects, safety and status
  • KPV can be found in Germany: Prices, Janoshik-COA and Versand | MyPeptide.eu
  • KPV can be found in Österreich: Prices, Janoshik-COA and Delivery | MyPeptide.eu
  • KPV open in Nederland: prices, Janoshik-COA in leverage | MyPeptide.eu
  • Oral or injectable KPV: what the studies say
  • KPV or BPC-157: what are the differences?
  • KPV vásárlás Magyarországon: ár, Janoshik COA és szállítás | MyPeptide.eu
  • Kupić KPV w Polsce: cena, COA Janoshik i dostawa | MyPeptide.eu
  • Kúpiť GHK-Cu na Slovensku: cena, COA Janoshik a doručenie | MyPeptide.eu
  • Kúpiť KPV na Slovensku: cena, COA Janoshik a dručenie | MyPeptide.eu
  • Kúpiť retatrutide na Slovensku: cena, COA a dodávateľ | MyPeptide.eu
  • Kupiti GHK-Cu u Hrvatskoj: cijena, Janoshik COA i dostava | MyPeptide.eu
  • Kupiti KPV u Hrvatskoj: cijena, Janoshik COA i dostava | MyPeptide.eu
  • Kupiti Retatrutide u Hrvatskoj: cijena, COA i dobavljač | MyPeptide.eu
  • Mistä ostaa KPV:tä Suomessa? Hinta, Janoshik-COA ja toimitus | MyPeptide.eu
  • MOTS-c: What is it, effects, studies and price (complete guide) | MyPeptide.eu
  • MOTS-c: Side effects, dangers, and reviews (what we know) | MyPeptide.eu
  • MOTS-c and weight loss: metabolism, insulin, what the studies say | MyPeptide.eu
  • MOTS-c and sport: the peptide that "mimics exercise," what the research says | MyPeptide.eu
  • MOTS-c vs SS-31 (elamipretide): Two mitochondrial peptides compared | MyPeptide.eu
  • MyPeptide reviews: is it a legit site?
  • Wave to buy GHK-Cu in Portugal: preço, COA Janoshik and entrega | MyPeptide.eu
  • Osta GHK-Cu Suomesta: hinta, Janoshik-COA ja toimitus | MyPeptide.eu
  • Osta retatrutide Suomesta: hinta, COA ja toimittaja | MyPeptide.eu
  • Copper peptides: GHK-Cu, AHK-Cu, differences and uses | MyPeptide.eu
  • Pharmaceutical Grade Peptides Europe — HPLC 99%+
  • R3 shot, injection, or pen: the different forms of retatrutide | MyPeptide.eu
  • Pirkt GHK-Cu Latvijā: cena, Janoshik COA un piegāde | MyPeptide.eu
  • Pirkt KPV Latvijā: cena, Janoshik COA un piegāde | MyPeptide.eu
  • Pirkt Retatrutide Latvijā: cena, COA un piegādātājs | MyPeptide.eu
  • Pirkti GHK-Cu Lietuvoje: kaina, Janoshik COA ir pristatymas | MyPeptide.eu
  • Pirkti KPV Lietuvoje: kaina, Janoshik COA ir pristatymas | MyPeptide.eu
  • Pirkti Retatrutide Lietuvoje: kaina, COA ir tiekėjas | MyPeptide.eu
  • Shipping Policy
  • Privacy Policy – MyPeptide
  • Return and refund policy
  • GHK-Cu price in Europe: 13 sellers compared
  • Price of retatrutide (R3) in France: from €5/mg
  • R3 (retatrutide): Is it a medication? Pharmacy, prescription, tablet | MyPeptide.eu
  • Research Peptides Fast Shipping Europe — 2–5 Days
  • Retatrutide: legal status in Europe, country by country (2026)
  • Retatrutide France: supplier, prices from €5/mg, COA Janoshik | MyPeptide.eu
  • Retatrutide kaufen in Deutschland: Preis ab 5 €/mg, Janoshik-COA | MyPeptide.eu
  • Retatrutide kaufen in Österreich: Preis, COA und Anbieter | MyPeptide.eu
  • Retatrutide kopen in Nederland en België: prices, COA & leverage | MyPeptide.eu
  • Retatrutide kupić w Polsce: cena, COA i dostawca | MyPeptide.eu
  • Retatrutide Luxembourg: Price, Purchase & Reliable Supplier | MyPeptide.eu
  • Retatrutide prezzo e acquisto in Italia: da 5 €/mg, COA Janoshik | MyPeptide.eu
  • Retatrutide vásárlás Magyarországon: ár, COA és beszállító | MyPeptide.eu
  • Retatrutide vs. cagrilintide: Differences, mechanisms, and trials | MyPeptide.eu
  • Retatrutide vs tesamorelin: differences, targets, and studies | MyPeptide.eu
  • Tesamorelin: What is it, studies, status and price | MyPeptide.eu
  • Tesamorelin: Side effects, dangers, and reviews (clinical trials) | MyPeptide.eu
  • Tesamorelin and visceral (belly) fat: what the trials show | MyPeptide.eu
  • Tesamorelin and bodybuilding: what the research really says | MyPeptide.eu
  • Weight Loss Peptides Europe — Retatrutide & More
  • Αγορά GHK-Cu στην Ελλάδα: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά GHK-Cu στην Κύπρο: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά KPV στην Ελλάδα: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά KPV στην Κύπρο: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά Retatrutide στην Ελλάδα: Τιμή, COA και Προμηθευτής | MyPeptide.eu
  • Αγορά Retatrutide στην Κύπρο: Τιμή, COA και Προμηθευτής | MyPeptide.eu
  • Buy Research Peptides — Retatrutide, GHK-Cu, NAD+ | MyPeptide.eu
  • Cart
  • Quality
  • Checkout
  • Contact
  • My account
By Samayyy / May 3, 2026
Weight loss
10-minute read

Peptide for weight loss Which ones work? 2026 Guide

Semaglutide, tirzepatide, retatrutide, cagrilintide, brenipatide, AOD-9604: peptides studied for weight loss, ranked according to what studies actually show, with their mechanisms and status in 2026.

In short

The peptides that have shown the greatest weight loss in studies act on satiety hormones: retatrutide (−24.2% in phase 2, not approved), tirzepatide (up to −22.5%, Mounjaro), the CagriSema combination (approximately −20%), and semaglutide (−14.9%, Wegovy). Other approaches (AOD-9604, MOTS-c, 5-Amino-1MQ) have yielded only modest results or have been observed in animal studies. In Europe, only semaglutide and tirzepatide are approved medications.

Introduction: Why peptides are at the heart of obesity research

Obesity is a complex disease involving hormonal, neuroendocrine, and metabolic dysregulations that go far beyond a simple calorie imbalance. Peptides—small signaling molecules naturally present in the body—act precisely on these dysregulations: regulation of appetite, lipid metabolism, energy expenditure, and insulin sensitivity.

Research into weight-loss peptides has accelerated dramatically since 2020, driven by the clinical successes of Semaglutide and Tirzepatide, which demonstrated that weight reductions of >15% were achievable pharmacologically. Retatrutide (>20%) and next-generation molecules are pushing these boundaries even further.

⚠️ For scientific use only

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are licensed, prescription medications. The other molecules in this guide are research compounds not approved as drugs. The information below is intended for laboratory researchers only.

Which peptide helps with weight loss? What studies show

Not all "slimming peptides" are created equal: some have clinical trials involving thousands of participants, while others have only results in mice. Classified by level of evidence:

  • Large-scale clinical trials : semaglutide (−14.9%, STEP-1), tirzepatide (up to −22.5%, SURMOUNT-1), CagriSema (approximately −20%, REDEFINE 1) and retatrutide (−24.2% in phase 2, phase 3 TRIUMPH ongoing).
  • Shorter or targeted trials : cagrilintide alone (−10.8% in 26 weeks, phase 2), tesamorelin (visceral fat), AOD-9604 (failure in phase 2b).
  • Data primarily preclinical : MOTS-c, humanin, 5-Amino-1MQ, BPC-157.

In trials, the most effective weight-loss molecules have one thing in common: they act on satiety hormones (GLP-1, GIP, amylin), often on several at once. Other avenues remain the subject of ongoing research.

What is a "tripeptide"?

Retatrutide is often referred to as a "tripeptide weight loss" because it acts on three receptors. However, it is a single peptide, not a mixture of three: it is called a triple agonist.

Category 1 — Incretin agonists (GLP-1, GIP, Glucagon)

This is the most powerful and clinically documented family for body weight reduction.

Semaglutide — GLP-1 mono-agonist

Semaglutide (Ozempic, Wegovy) is a native GLP-1 analog with 94% homology, conjugated to a C18 diacid chain, which gives it a half-life of approximately 7 days (weekly administration). It reduces appetite primarily via GLP-1 receptors in the hypothalamus and slows gastric emptying.

  • Average weight loss: -14.9% in 68 weeks (STEP-1 study, 2021)
  • Improvement in blood sugar, lipids and blood pressure
  • Tolerability: frequent nausea and vomiting during the titration phase

Tirzepatide — Dual GLP-1/GIP agonist

Tirzepatide (LY3298176, Mounjaro and Zepbound) is a dual GLP-1/GIP agonist developed by Eli Lilly. The addition of the GIP agonist potentiates the insulinotropic effect and improves insulin sensitivity in adipose tissue.

  • Weight loss: -22.5% at a dose of 15 mg over 72 weeks (SURMOUNT-1)
  • HbA1c reduction greater than insulin in T2DM studies
  • FDA approval (Zepbound) for obesity in 2023

Retatrutide — GLP-1/GIP/Glucagon triple agonist

Retatrutide (LY3437943) represents the cutting edge of current research. The addition of glucagon agonism to the two aforementioned receptors increases basal energy expenditure and hepatic lipolysis—a fundamental mechanistic difference.

  • Weight loss: -24.2% over 48 weeks at 12 mg (phase 2, NEJM 2023)
  • Reduction of liver fat by -82% (MRI-PDFF)
  • TRIUMPH Phase 3 Program in progress

→ Read the complete guide on Retatrutide

Brenipatide — monthly dual GIP/GLP-1 agonist

Brenipatide (LY3537031, Eli Lilly) activates the same receptors as tirzepatide, but it is designed for once-monthly administration. It is not primarily being studied for weight loss; its phase 3 program focuses on alcohol use disorder. It is of interest to research investigating the link between incretins and reward circuits.

→ Brenipatide Guide · Brenipatide 1 mg for research

Category 1 bis — Amylin analogues

Amylin is a hormone released with insulin after a meal. It enhances satiety through a different pathway than GLP-1, which explains the benefit of combining them.

Cagrilintide — a long-acting amylin analogue

Cagrilintide (Novo Nordisk) is an amylin analogue administered once weekly in trials. On its own, it reduced weight by 10.8% over 26 weeks in phase 2 (The Lancet, 2021).

  • CagriSema : cagrilintide + semaglutide combination, approximately −20% in 68 weeks (REDEFINE 1 trial)
  • Complementary mechanism of GLP-1: slowing of gastric emptying and satiety via the brainstem

→ Cagrilintide Guide · Retatrutide vs cagrilintide · Cagrilintide 5 mg for research

Category 2 — Growth hormone (GH) fragments

AOD-9604 — GH Fragment 176-191

AOD-9604 (Advanced Obesity Drug) is a synthetic fragment of amino acids 176-191 of human GH. Unlike complete GH, it has no effect on growth or blood glucose levels, but it is said to retain the lipolytic properties of GH.

Its supposed mechanism involves the activation of beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis and inhibiting lipogenesis.

  • Studies in rats and mouse models: significant reduction in fat mass
  • Phase 2b clinical trials (2007): weight loss no superior to placebo, development stopped for obesity
  • No effect on IGF-1 or blood glucose — favorable preclinical safety profile
  • Used in research to understand GH-independent lipolytic pathways

Ipamorelin + CJC-1295 — GH Secretagogues

The combination Ipamorelin (selective ghrelin agonist) + CJC-1295 (GHRH analogue) stimulates the physiological secretion of GH by the pituitary gland. The released GH promotes lipolysis and the preservation of lean mass, particularly during calorie restriction.

  • Particular interest in research on body composition (fat mass/lean mass ratio)
  • Effect on visceral lipolysis > subcutaneous according to some studies
  • No direct hypoglycemic effect (unlike insulin)

→ Read the CJC-1295 + Ipamorelin guide

Tesamorelin — GHRH analogue and visceral fat

Tesamorelin stimulates the secretion of growth hormone. It is one of the few peptides in this family that has been approved: it was approved in the United States in 2010 (Egrifta) for treating excess abdominal fat in patients living with HIV, with a reduction in visceral fat of approximately 15% in trials. It acts on fat distribution more than on total weight.

→ Tesamorelin: studies and status · Tesamorelin 10 mg for research

Category 3 — Hypothalamic-acting peptides

MOTS-c — Mitochondrial Peptide

MOTS-c is a mitochondrial genome peptide (12S rRNA), identified in 2015. Studies in mice show that it improves insulin sensitivity, reduces high-fat diet-induced obesity, and increases spontaneous physical activity.

  • Mechanism: activation of the AMPK pathway in muscle and adipose tissue
  • Reduction of insulin resistance in diabetic mouse models
  • Few human studies to date — an emerging field

→ MOTS-c Guide

Humanin — Cytoprotective mitochondrial peptide

Humanin is another mitochondrial peptide that improves insulin sensitivity and reduces apoptosis in pancreatic islets. Preclinical studies suggest a role in the regulation of glucose and fat mass.

Category 4 — Peptides with indirect metabolic action

BPC-157 — Gastric Protection and Metabolism

BPC-157 (Body Protection Compound-157), primarily known for its effects on wound healing and gastric protection, also presents interesting data on lipid metabolism and regulation of the gut-brain axis in some preclinical models.

→ Read the complete BPC-157 guide

Two frequently cited molecules that are not peptides

Tesofensine — triple reuptake inhibitor

Tesofensine blocks the reuptake of serotonin, dopamine, and norepinephrine, thereby reducing food intake through a central action. Weight loss of 10% to 14% in phase 2. It is not a peptide but a small molecule; it is included here because it is often compared to peptides.

5-Amino-1MQ — NNMT inhibitor

5-Amino-1MQ blocks NNMT, an enzyme highly present in adipose tissue. In obese mice, it reduced fat mass without decreasing food intake. No clinical trials have been published to date. 5-Amino-1MQ 10 mg for research

Comparative table of peptides for weight loss

Peptide Primary target Measured weight loss Stadium At MyPeptide
Retatrutide GLP-1/GIP/glucagon -24.2% (phase 2) Phase 3 View product
Tirzepatide GLP-1/GIP up to -22.5% Authorized (Mounjaro) View product
CagriSema Amylin + GLP-1 approximately -20% Phase 3 —
Semaglutide GLP-1 -14.9% Authorized (Wegovy) —
Cagrilintide Amyline -10.8% (26 weeks) Phase 2-3 View product
Brenipatide GIP/GLP-1 Unpublished Phase 3 (alcohol) View product
Tesamorelin GHRH Visceral fat ≈ −15% Approved in the United States (HIV) View product
CJC-1295 + Ipamorelin GHRH/ghrelin Body composition Preclinical —
AOD-9604 Fragment of GH Modest Stopped after phase 2b —
MOTS-c mitochondrial AMPK Mouse Preclinical View product

Common characteristics of peptides that promote weight loss

Regardless of their specific mechanisms, the most effective peptides for body weight reduction in research share several characteristics:

  • They act on several pathways simultaneously (multi-target > single-target)
  • They preserve lean mass better than calorie-only approaches.
  • Their side effects are primarily gastrointestinal and dose-dependent.
  • A long duration of action (half-life > 24h) is associated with better efficacy
  • Efficiency is generally dose-dependent with a plateau relationship

Frequently asked questions about peptides and weight loss

Which peptide is the most effective for weight loss?

In published trials, retatrutide, a triple GLP-1/GIP/glucagon agonist, achieved the greatest weight loss: −24.2% over 48 weeks in phase 2 (NEJM, 2023). This was followed by tirzepatide (up to −22.5% in SURMOUNT-1), the CagriSema combination (approximately −20%), and semaglutide (−14.9% in STEP-1). Retatrutide remains in phase 3 and is not approved.

Which weight loss peptides are authorized as medications?

In Europe, only semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are authorized, and only by prescription. Retatrutide, cagrilintide, brenipatide, MOTS-c, and AOD-9604 are research compounds not approved as medications.

What is the "tripeptide" for weight loss?

The word generally refers to retatrutide, so named because it acts on three receptors (GLP-1, GIP, and glucagon). However, it is a single peptide, not a chain of three. In biochemistry, a tripeptide is a chain of three amino acids, like GHK-Cu, regardless of weight.

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors (GLP-1 and GIP) and is approved (Mounjaro). Retatrutide adds the glucagon receptor, which increases energy expenditure and fat burning in the liver: it performed better in phase 2 (−24.2% vs. −22.5%), but its phase 3 trials are ongoing.

Read also
  • Semaglutide vs Retatrutide vs Tirzepatide: a scientific comparison of GLP-1 peptides
  • Retatrutide: the triple agonist peptide that is revolutionizing obesity research
  • How the GLP-1 receptor works: molecular mechanisms and research implications

Complete catalog of research peptides

MyPeptide offers retatrutide, tirzepatide, cagrilintide, brenipatide, tesamorelin, MOTS-c, and 5-Amino-1MQ for research, each with its own independent Janoshik analysis report. Shipping from the European Union in 2 to 5 business days.

Sources
  • Semaglutide — Wilding JPH et al., STEP 1 trial, N Engl J Med, 2021.
  • Tirzepatide — Jastreboff AM et al., SURMOUNT-1 trial, N Engl J Med, 2022.
  • Retatrutide — Jastreboff AM et al., phase 2 trial, N Engl J Med, 2023 (PubMed 37366315).
  • Cagrilintide — Lau DCW et al., phase 2 trial, The Lancet, 2021.
  • CagriSema — Garvey WT et al., REDEFINE 1 trial, N Engl J Med, 2025.
  • Tesamorelin — Falutz J et al., N Engl J Med, 2007.

View the catalog → Buy R3 Reta 10 mg →

Warning : All peptides mentioned are research compounds not approved as medicines. The data presented is from scientific publications and does not constitute medical advice. MyPeptide.eu products are intended exclusively for scientific laboratory research.

📦 Retatrutide available for research in Europe

France · Belgium · Germany · Spain · Netherlands

And tesamorelin? It doesn't cause weight loss: it primarily reduces visceral fat, by about 15% over 26 weeks in trials. See tesamorelin and visceral fat and retatrutide vs tesamorelin.

And what about MOTS-c? This mitochondrial peptide affects glucose utilization by muscles rather than appetite. See MOTS-c and weight loss and our MOTS-c guide.

Scientific sources

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — Jastreboff AM et al. (2023)
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity — Wilding JPH et al. (2021)
  3. The expanding incretin universe: from basic biology to clinical translation — Drucker DJ et al. (2023)
Previous

GHK-Cu: the copper peptide and its effects on the skin, repair and aging

Following

MOTS-c: the mitochondrial peptide that mimics exercise

Leave a comment Cancel reply

Your email address will not be published. Required fields are indicated with an asterisk (*). *

Warning : The products offered on MyPeptide.eu are intended exclusively for scientific research in the laboratory.

© 2026 MyPeptide.eu — All rights reserved · Designed in Europe · GDPR compliant
Certificates of AnalysisIs MyPeptide legit?Terms & ConditionsPrivacy PolicyTerms of ServiceReturn & Refund PolicyShipping PolicyLegal Notice
100% secure paymentVisaApple PayGoogle Pay
FRENDEITESPTNLPLSV
Back to top